Planting Hope for a Greener Tomorrow: World Environment Day Event at Manipal Hospital Malleshwaram Rooted for Environmental Awareness & Action
BANGALORE, India , June 9, 2025 /PRNewswire/ — On the occasion of World Environment Day, 5th June 2025 , Manipal Hospital Malleshwaram hosted a meaningful event titled 'Let's root for the future – literally!' that brought together school students, community members, dignitaries, and healthcare experts to promote environmental awareness and action.
The event was graced by Mr. N. Ravindrakumar, Deputy Conservator of Forests, Bengaluru Urban Division, as the Chief Guest, and Mr. Abdul Hafeez , Hospital Director, Manipal Hospital Malleshwaram, who joined hands with students, neighbourhood residents, and hospital staff to plant saplings and share the message of environmental sustainability. The event was also attended by eminent health experts, including Dr. G. K. Prakash, Consultant – Nephrology, and Transplant Physician, Dr. Vikas G. K., Consultant – Emergency Medicine, and Dr. Puneeth B. S., Consultant – Medical Gastroenterology, who aimed to bring sustainable change for a greener tomorrow.
The day began with a plantation drive at Jagadguru Sri Adi Shankaracharya Udyanavana, a BBMP park maintained by the hospital. Students from Hymamshu Jyothi Kala Peetha School and Cluny Convent High School, accompanied by their teachers, along with the chief guest, community members, consultants, and senior citizens, took part in the activity.
As part of a learning experience, a guided tour of the park was organized, where students could explore posters that explained the ecological significance of various trees. This was followed by engaging activities such as an Essay Competition on the theme 'Ending Plastic Pollution Globally' and Handprint Tree Board as a pledge towards protecting the environment.
A special highlight of the event involved students getting a closer look inside the MARS Ambulance (Manipal Ambulance Response Service), learning about its services, and how it connects to community well-being during emergencies.
Mr. N. Ravindrakumar, Deputy Conservator of Forests, Bengaluru Urban Division, stated, 'On this World Environment Day, it's encouraging for the hospital to invite students to participate in the sapling plantation drive. Children are the future stewards of our planet, and it is crucial to instill in them a sense of responsibility towards environmental conservation. Educating them about the impact of environmental pollution, like air and water contamination, is equally important. Initiatives like this plantation drive serve as powerful, experiences that nurture awareness and action in the young minds of tomorrow.'
Ms Rajani, Subject Teacher, Hymamshu Jyothi Kala Peetha School, said, 'Today, as we have gathered to attend the World Environment Day celebration by Manipal Hospital Malleshwaram, I would like to thank the team for the opportunity offered to our students. It's such an amazing program to participate and create awareness to protect our environment. We should definitely inculcate these good habits to save our surroundings and work towards a better and greener future.'
Ms. Chetana, Computer Science Teacher, Cluny Convent High School, noted, 'We were delighted to take part in the sapling plantation drive. The students also enthusiastically participated in the essay writing and quiz competitions. I had always associated Manipal Hospital primarily with patient care, but today I witnessed their admirable commitment to promoting environmental awareness and sustainability. Their initiative to engage young minds in such meaningful activities is truly commendable.'
Through this initiative, Manipal Hospital Malleshwaram inspired kids to be the Environmental Ambassadors of Tomorrow, where they gain environmental awareness to bring positive change for a greener urban ecosystem.
For more information, please visit: https://www.manipalhospitals.com/malleshwaram/
Photo: https://mma.prnewswire.com/media/2706074/Manipal_Hospital_Malleshwaram_1.jpg
Photo: https://mma.prnewswire.com/media/2706075/Manipal_Hospital_Malleshwaram_2.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Study Shows That Existing Drug Class May Help Patients with Skin Cancer That Resists Standard Treatments
NEW YORK, June 10, 2025 /PRNewswire/ -- Increased activity in a specific biological pathway may explain why many patients with a deadly form of skin cancer do not respond to the latest cancer treatments, a new study shows. Publishing in the journal Cancer Research online June 10, the study featured data generated from experiments with human tissues and cells from patients with advanced melanoma that were implanted into mice. Results uncovered therapeutic targets that could limit melanoma growth in patients whose cancer failed to respond to initial treatment with immune checkpoint inhibitors. Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the study focused on a subgroup of melanoma patients with mutations in the neurofibromin 1 (NF1) gene. NF1 mutations — random changes in the molecular "letters" that make up this gene's DNA code — are just one type among several mutations, including those in the BRAF, NRAS, and PARP genes, that are linked to many cases of cancer, particularly melanoma. As many as 27% of melanoma patients are estimated to have NF1 mutations. While immunotherapy, which stimulates the immune system to attack cancer cells as it would an invading virus, has proved to be a successful treatment, it does not work well for more than half of NF1-mutant melanoma patients. "There is a pressing need for new drug therapies for melanoma patients with neurofibromin 1 mutations that do not respond to the latest immunotherapy, and for which there are no subsequent effective treatment options," said study lead investigator Milad Ibrahim, PhD. Ibrahim is a postdoctoral fellow in the Dr. Iman Osman Laboratory in the Ronald O. Perelman Department of Dermatology at the NYU Grossman School of Medicine. To investigate why these patients were treatment resistant, investigators examined tumor cells from 30 melanoma patients who did not respond to immunotherapy. NF1 mutations were found in 40% of these melanoma samples. The samples came from NYU Langone's extensive repository from more than 6,000 melanoma patients. Molecular testing showed that the signaling pathway built around a protein called epidermal growth factor receptor (EGFR) was more active in NF1 mutant melanoma cells than in cells with other melanoma-gene mutations. Increased EGFR activity has long been linked to abnormal cell growth in tumors and shorter survival with various cancers. The researchers also found that NF1 mutant melanoma cells depended on increased EGFR activity for survival, regardless of the presence of other mutations. Because EGFR-inhibiting drugs are already used to treat some head and neck cancers, as well as colorectal and lung cancers, researchers then tested two drugs in the class, cetuximab and afatinib, in both NF1 mutant cell cultures and cancer cell lines without NF1 mutations. After transplanting both tumor cell types into mice and treating them with these drugs, results showed that both EGFR inhibitors were effective against cells and transplanted tumors with NF1 mutations, and they had no effect on melanomas without NF1 mutations. "Our study results reveal a unique vulnerability in melanoma patients with neurofibromin 1 mutations, that an overexpression of the epidermal growth factor receptor pathway is essential for their survival and growth," said study senior investigator Iman Osman, MD. Osman is the Rudolf L. Baer Professor in the Ronald O. Perelman Department of Dermatology at the NYU Grossman School of Medicine and a member of the Perlmutter Cancer Center. Osman is also director of the interdisciplinary melanoma program and associate dean of clinical research strategy at NYU Langone. "While further tests are needed, our results support a novel approach of deploying EGFR inhibitors either alone or in combination with other immunotherapies for treatment of melanoma patients whose tumors harbor NF1 mutation," said study co-senior investigator Markus Schober, PhD. Schober is an associate professor in the Ronald O. Perelman Department of Dermatology at the NYU Grossman School of Medicine and a member of the Perlmutter Cancer Center. However, Schober says this requires further testing in a clinical trial, which the research team plans to develop. He adds that if trial findings prove successful, the team's research could provide a lifeline for many of these melanoma patients. Metastatic melanoma, as the disease is formally called, kills nearly 10,000 Americans annually. Funding for the study was provided by National Institutes of Health grants P50CA225450, U54CA263001, and P30CA016087. Additional funding support was provided by Melanoma Research Foundation grant 1287389. Besides Ibrahim, Osman and Schober, NYU Langone researchers involved in this study are co-investigators Irineu Illa-Bochaca, George Jour, Eleazar Vega-Saenz de Miera, Joseph Fracasso, Kelly Ruggles, and Jeffrey Weber. About NYU Langone HealthNYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise. Media Contact Shira Polan (from June 6 to June 10) David March (after June 10) STUDY DOI10.1158/ STUDY LINKhttps:// View original content to download multimedia: SOURCE NYU Langone Health System Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Fidelis Care Maternal Health Grant Applications Now Open to Providers and Organizations Across New York State
Grants aim to support innovative strategies in postpartum care and maternal mental health in underserved and vulnerable communities LONG ISLAND CITY, N.Y., June 10, 2025 /PRNewswire/ -- Fidelis Care, a statewide health plan with more than 2.4 million members in New York State and a Centene Corporation company, has opened the application process for its 2025 maternal health grant program. The grants, open to healthcare providers and community-based organizations in New York, aim to fund programs that support innovative strategies in postpartum care and maternal mental health. The application is available at The deadline to apply is 5 p.m. July 8, 2025. Postpartum care and maternal mental health are critical components of long-term health and well-being for new mothers and their families. The Substance Abuse and Mental Health Services Administration (SAMHSA) says mental health conditions, including depression and anxiety, are among the most common complications of pregnancy, affecting an estimated one in five individuals annually in the United States. Postpartum care attendance is inconsistent, with mean attendance rates in the U.S. around 72%, and even lower among the most vulnerable populations, such as those served by Federally Qualified Health Centers, where non-attendance can reach 43%. Access to health insurance has been associated with higher postpartum visit attendance, which is essential for screening and addressing both physical and mental health needs after childbirth. "As a healthcare community, we must recognize that supporting mothers after childbirth is just as vital as caring for them during pregnancy," said Fidelis Care Chief Medical Officer Dr. Vincent Marchello. "Ensuring access to postpartum care and mental health services not only improves the well-being of mothers but also strengthens families and communities as a whole." Fidelis Care plans to announce the recipients of its 2025 maternal health grants in August. About Fidelis Care Fidelis Care is a mission-driven health plan offering quality, affordable coverage for children and adults of all ages and at all stages of life. With more than 2.4 million members statewide, Fidelis Care believes that all New Yorkers should have access to affordable, quality health insurance. Follow us on LinkedIn at Instagram at @fideliscare, and on Facebook at For more information, call Fidelis Care at1-888-FIDELIS (1-888-343-3547) or visit Media ContactMediaInquiries@ View original content to download multimedia: SOURCE Fidelis Care Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Fidelis Care Maternal Health Grant Applications Now Open to Providers and Organizations Across New York State
Grants aim to support innovative strategies in postpartum care and maternal mental health in underserved and vulnerable communities LONG ISLAND CITY, N.Y., June 10, 2025 /PRNewswire/ -- Fidelis Care, a statewide health plan with more than 2.4 million members in New York State and a Centene Corporation company, has opened the application process for its 2025 maternal health grant program. The grants, open to healthcare providers and community-based organizations in New York, aim to fund programs that support innovative strategies in postpartum care and maternal mental health. The application is available at The deadline to apply is 5 p.m. July 8, 2025. Postpartum care and maternal mental health are critical components of long-term health and well-being for new mothers and their families. The Substance Abuse and Mental Health Services Administration (SAMHSA) says mental health conditions, including depression and anxiety, are among the most common complications of pregnancy, affecting an estimated one in five individuals annually in the United States. Postpartum care attendance is inconsistent, with mean attendance rates in the U.S. around 72%, and even lower among the most vulnerable populations, such as those served by Federally Qualified Health Centers, where non-attendance can reach 43%. Access to health insurance has been associated with higher postpartum visit attendance, which is essential for screening and addressing both physical and mental health needs after childbirth. "As a healthcare community, we must recognize that supporting mothers after childbirth is just as vital as caring for them during pregnancy," said Fidelis Care Chief Medical Officer Dr. Vincent Marchello. "Ensuring access to postpartum care and mental health services not only improves the well-being of mothers but also strengthens families and communities as a whole." Fidelis Care plans to announce the recipients of its 2025 maternal health grants in August. About Fidelis Care Fidelis Care is a mission-driven health plan offering quality, affordable coverage for children and adults of all ages and at all stages of life. With more than 2.4 million members statewide, Fidelis Care believes that all New Yorkers should have access to affordable, quality health insurance. Follow us on LinkedIn at Instagram at @fideliscare, and on Facebook at For more information, call Fidelis Care at1-888-FIDELIS (1-888-343-3547) or visit Media ContactMediaInquiries@ View original content to download multimedia: SOURCE Fidelis Care Sign in to access your portfolio
